MedTrace Logo

Erythropoietin in Acute Myocardial Infarction

NCT00149058 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2005-09-08

No results posted yet for this study

Summary

Erythropoietin (EPO) is a naturally occuring hormone which regulates the body's response to lack of oxygen and controls the number of red cells in the blood. Recent studies in animals have shown that EPO has protective effects when organs such as the heart and brain are injured by lack of oxygen due to reduced blood supply.

We wish to test the idea that giving a patient, who is having a heart attack, an injection of EPO will reduce the size of the heart attack.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

Erythropoietin

Sponsors & Collaborators

  • Hammersmith Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Jaspal S Kooner · Hammersmith Hospitals NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2008-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00149058 on ClinicalTrials.gov